Cargando…

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

SIMPLE SUMMARY: Molecular characterization of advanced non-small-cell lung cancer (NSCLC) is mandatory before any treatment decision making. Next-generation sequencing (NGS) approaches represent the best strategy in this context. In our study, we analyzed a case series of young (under 65 years old)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulivi, Paola, Urbini, Milena, Petracci, Elisabetta, Canale, Matteo, Dubini, Alessandra, Bartolini, Daniela, Calistri, Daniele, Cravero, Paola, Fonzi, Eugenio, Martinelli, Giovanni, Priano, Ilaria, Andrikou, Kalliopi, Bronte, Giuseppe, Crinò, Lucio, Delmonte, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139648/ https://www.ncbi.nlm.nih.gov/pubmed/35625958 http://dx.doi.org/10.3390/cancers14102352

Ejemplares similares

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients
por: Pasini, Luigi, et al.
Publicado: (2022)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer
por: Rossi, Tania, et al.
Publicado: (2019)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells
por: Zamagni, Alice, et al.
Publicado: (2020)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)

Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications
por: Urbini, Milena, et al.
Publicado: (2021)

How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance
por: Balzi, William, et al.
Publicado: (2021)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19
por: Bravaccini, Sara, et al.
Publicado: (2021)

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection
por: Monti, Manlio, et al.
Publicado: (2017)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients
por: Tedaldi, Gianluca, et al.
Publicado: (2020)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
por: Canale, Matteo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a2di1f7cr9v633ngifm6udc739